The immunology of traumatic brain injury: a prime target for Alzheimer's disease prevention

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Giunta, Brian ^a,b   Obregon, Demian ^a,b   Velisetty, Renuka ^b   Sanberg, Paul R ^b   Borlongan, Cesar V ^b   Tan, Jun ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's disease; Cytokines; Flavonoids; Microglia phenotype; Traumatic brain injury

Indexed keywords

AMYLOID BETA PROTEIN; APIGENIN; EPIGALLOCATECHIN GALLATE; FISH OIL; FLAVONOID; GENISTEIN; GINKGO BILOBA EXTRACT; INTERLEUKIN 6; LUTEOLIN; PLACEBO; QUERCETIN; RESVERATROL; WOGONIN;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ANTIGEN PRESENTING CELL; BRAIN CONCUSSION; BRAIN DYSFUNCTION; CELL ACTIVATION; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; HUMAN; IMMUNOPATHOLOGY; INNATE IMMUNITY; MEDICAL HISTORY; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PROPHYLAXIS; REVIEW; RISK FACTOR; RISK REDUCTION; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT;

EID: 84864403888     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-185     Document Type: Review

References (100)

1. Chen XH, Johnson VE, Uryu K, Trojanowski JQ, Smith DH. A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol 2009, 19:214-223. 10.1111/j.1750-3639.2008.00176.x, 3014260, 18492093.
2. Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, Lossinsky AS, Graves MC, Gustavson A, Sayre J, Sofroni E, Suarez T, Chiappelli F, Bernard G. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis 2005, 7:221-232. discussion 255-262.
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007, 3:186-191. 10.1016/j.jalz.2007.04.381, 19595937.
4. Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J Neurol Neurosurg Psychiatry 2003, 74:857-862. 10.1136/jnnp.74.7.857, 1738550, 12810767.
5. Geddes JF, Vowles GH, Nicoll JA, Revesz T. Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol 1999, 98:171-178. 10.1007/s004010051066, 10442557.
6. Gentleman SM, Leclercq PD, Moyes L, Graham DI, Smith C, Griffin WS, Nicoll JA. Long-term intracerebral inflammatory response after traumatic brain injury. Forensic Sci Int 2004, 146:97-104. 10.1016/j.forsciint.2004.06.027, 15542269.
7. Kotapka MJ, Graham DI, Adams JH, Gennarelli TA. Hippocampal pathology in fatal non-missile human head injury. Acta Neuropathol 1992, 83:530-534. 10.1007/BF00310031, 1621508.
8. Maxwell WL, MacKinnon MA, Stewart JE, Graham DI. Stereology of cerebral cortex after traumatic brain injury matched to the Glasgow outcome score. Brain 2010, 133(Pt 1):139-160.
9. Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S, Moss T, Griffin WS. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000, 47:365-368. 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.0.CO;2-G, 10716257.
10. Smith DH, Chen XH, Nonaka M, Trojanowski JQ, Lee VM, Saatman KE, Leoni MJ, Xu BN, Wolf JA, Meaney DF. Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. J Neuropathol Exp Neurol 1999, 58:982-992. 10.1097/00005072-199909000-00008, 10499440.
11. Smith DH, Chen XH, Pierce JE, Wolf JA, Trojanowski JQ, Graham DI, McIntosh TK. Progressive atrophy and neuron death for one year following brain trauma in the rat. J Neurotrauma 1997, 14:715-727. 10.1089/neu.1997.14.715, 9383090.
12. Chandra V, Philipose V, Bell PA, Lazaroff A, Schoenberg BS. Case-control study of late onset 'probable Alzheimer's disease'. Neurology 1987, 37:1295-1300. 10.1212/WNL.37.8.1295, 3614650.
13. Amaducci LA, Fratiglioni L, Rocca WA, Fieschi C, Livrea P, Pedone D, et al. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology 1986, 36:922-931. 10.1212/WNL.36.7.922, 3714054.
14. Broe GA, Henderson AS, Creasey H, McCusker E, Korten AE, Jorm AF, Longley W, Anthony JC. A case-control study of Alzheimer's disease in Australia. Neurology 1990, 40:1698-1707. 10.1212/WNL.40.11.1698, 2146525.
15. Lye TC, Shores EA. Traumatic brain injury as a risk factor for Alzheimer's disease: a review. Neuropsychol Rev 2000, 10:115-129. 10.1023/A:1009068804787, 10937919.
16. Katzman R, Aronson M, Fuld P, Kawas C, Brown T, Morgenstern H, Frishman W, Gidez L, Eder H, Ooi WL. Development of dementing illnesses in an 80-year-old volunteer cohort. Ann Neurol 1989, 25:317-324. 10.1002/ana.410250402, 2712531.
17. Williams DB, Annegers JF, Kokmen E, O'Brien PC, Kurland LT. Brain injury and neurologic sequelae: a cohort study of dementia, parkinsonism, and amyotrophic lateral sclerosis. Neurology 1991, 41:1554-1557. 10.1212/WNL.41.10.1554, 1922795.
18. Ferini-Strambi L, Smirne S, Garancini P, Pinto P, Franceschi M. Clinical and epidemiological aspects of Alzheimer's disease with presenile onset: a case control study. Neuroepidemiology 1990, 9:39-49. 10.1159/000110750, 2330070.
19. Johnson VE, Stewart W, Smith DH. Traumatic brain injury and amyloid-beta pathology: a link to Alzheimer's disease?. Nat Rev Neurosci 2010, 11:361-370.
20. Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, Phillips C, Gau BA, Welsh-Bohmer KA, Burke JR, Guralnik JM, Breitner JC. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 2000, 55:1158-1166. 10.1212/WNL.55.8.1158, 11071494.
21. Nagamoto-Combs K, McNeal DW, Morecraft RJ, Combs CK. Prolonged microgliosis in the rhesus monkey central nervous system after traumatic brain injury. J Neurotrauma 2007, 24:1719-1742. 10.1089/neu.2007.0377, 18001202.
22. Schofield PW, Tang M, Marder K, Bell K, Dooneief G, Chun M, Sano M, Stern Y, Mayeux R. Alzheimer's disease after remote head injury: an incidence study. J Neurol Neurosurg Psychiatry 1997, 62:119-124. 10.1136/jnnp.62.2.119, 486721, 9048710.
23. Gedye A, Beattie BL, Tuokko H, Horton A, Korsarek E. Severe head injury hastens age of onset of Alzheimer's disease. J Am Geriatr Soc 1989, 37:970-973.
24. Nemetz PN, Leibson C, Naessens JM, Beard M, Kokmen E, Annegers JF, Kurland LT. Traumatic brain injury and time to onset of Alzheimer's disease: a population-based study. Am J Epidemiol 1999, 149:32-40. 10.1093/oxfordjournals.aje.a009724, 9883791.
25. Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H, Green RC, Sadovnick AD, Duara R, DeCarli C, Johnson K, Go RC, Growdon JH, Haines JL, Kukull WA, Farrer LA. Head injury and the risk of AD in the MIRAGE study. Neurology 2000, 54:1316-1323. 10.1212/WNL.54.6.1316, 10746604.
26. Guskiewicz KM, Marshall SW, Bailes J, McCrea M, Cantu RC, Randolph C, Jordan BD. Association between recurrent concussion and late-life cognitive impairment in retired professional football players. Neurosurgery 2005, 57:719-726. discussion 719-726.
27. Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1994, 57:419-425. 10.1136/jnnp.57.4.419, 1072869, 8163989.
28. Ikonomovic MD, Uryu K, Abrahamson EE, Ciallella JR, Trojanowski JQ, Lee VM, Clark RS, Marion DW, Wisniewski SR, DeKosky ST. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol 2004, 190:192-203. 10.1016/j.expneurol.2004.06.011, 15473992.
29. DeKosky ST, Abrahamson EE, Ciallella JR, Paljug WR, Wisniewski SR, Clark RS, Ikonomovic MD. Association of increased cortical soluble abeta42 levels with diffuse plaques after severe brain injury in humans. Arch Neurol 2007, 64:541-544. 10.1001/archneur.64.4.541, 17420316.
30. Jordan BD. Chronic traumatic brain injury associated with boxing. Semin Neurol 2000, 20:179-185. 10.1055/s-2000-9826, 10946737.
31. Koshinaga M, Katayama Y, Fukushima M, Oshima H, Suma T, Takahata T. Rapid and widespread microglial activation induced by traumatic brain injury in rat brain slices. J Neurotrauma 2000, 17:185-192. 10.1089/neu.2000.17.185, 10757324.
32. Gehrmann J, Banati RB, Wiessner C, Hossmann KA, Kreutzberg GW. Reactive microglia in cerebral ischaemia: an early mediator of tissue damage?. Neuropathol Appl Neurobiol 1995, 21:277-289. 10.1111/j.1365-2990.1995.tb01062.x, 7494596.
33. Gehrmann J, Matsumoto Y, Kreutzberg GW. Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 1995, 20:269-287.
34. Town T, Nikolic V, Tan J. The microglial 'activation' continuum: from innate to adaptive responses. J Neuroinflammation 2005, 2:24. 10.1186/1742-2094-2-24, 1298325, 16259628.
35. Nagamoto-Combs K, Combs CK. Microglial phenotype is regulated by activity of the transcription factor, NFAT (nuclear factor of activated T cells). J Neurosci 2010, 30:9641-9646. 2914496, 20631193.
36. Ramlackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK, Turkheimer FE, Kinnunen KM, Gentleman S, Heckemann RA, Gunanayagam K, Gelosa G, Sharp DJ. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol 2011, 70:374-383. 10.1002/ana.22455, 21710619.
37. Thiel A, Radlinska BA, Paquette C, Sidel M, Soucy JP, Schirrmacher R, Minuk J. The temporal dynamics of poststroke neuroinflammation: a longitudinal diffusion tensor imaging-guided PET study with 11C-PK11195 in acute subcortical stroke. J Nucl Med 2010, 51:1404-1412. 10.2967/jnumed.110.076612, 20720039.
38. Gerhard A, Schwarz J, Myers R, Wise R, Banati RB. Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. NeuroImage 2005, 24:591-595. 10.1016/j.neuroimage.2004.09.034, 15627603.
39. Teasdale GM, Graham DI. Craniocerebral trauma: protection and retrieval of the neuronal population after injury. Neurosurgery 1998, 43:723-737. discussion 737-738, 10.1097/00006123-199810000-00001, 9766298.
40. Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T. Modulation of immune response by head injury. Injury 2007, 38:1392-1400. 10.1016/j.injury.2007.10.005, 18048036.
41. Carbonell WS, Grady MS. Regional and temporal characterization of neuronal, glial, and axonal response after traumatic brain injury in the mouse. Acta Neuropathol 1999, 98:396-406. 10.1007/s004010051100, 10502046.
42. Dietrich WD, Chatzipanteli K, Vitarbo E, Wada K, Kinoshita K. The role of inflammatory processes in the pathophysiology and treatment of brain and spinal cord trauma. Acta Neurochir Suppl 2004, 89:69-74. 10.1007/978-3-7091-0603-7_9, 15335103.
43. Morganti-Kossmann MC, Rancan M, Otto VI, Stahel PF, Kossmann T. Role of cerebral inflammation after traumatic brain injury: a revisited concept. Shock 2001, 16:165-177. 10.1097/00024382-200116030-00001, 11531017.
44. Zhang B, West EJ, Van KC, Gurkoff GG, Zhou J, Zhang XM, Kozikowski AP, Lyeth BG. HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res 2008, 1226:181-191. 2652585, 18582446.
45. Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, Town T, Tan J. Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation 2008, 5:51-62. 10.1186/1742-2094-5-51, 2615427, 19014446.
46. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 2004, 3:169-176. 10.1111/j.1474-9728.2004.00101.x, 15268750.
47. Marx F, Blasko I, Grubeck-Loebenstein B. Mechanisms of immune regulation in Alzheimer's disease: a viewpoint. Arch Immunol Ther Exp (Warsz) 1999, 47:205-209.
48. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 2008, 14:681-687. 2649699, 18516051.
49. Urrea C, Castellanos DA, Sagen J, Tsoulfas P, Bramlett HM, Dietrich WD. Widespread cellular proliferation and focal neurogenesis after traumatic brain injury in the rat. Restor Neurol Neurosci 2007, 25:65-76.
50. Harborne JB, Williams CA. Advances in flavonoid research since 1992. Phytochemistry 2000, 55:481-504. 10.1016/S0031-9422(00)00235-1, 11130659.
51. Jang S, Johnson RW. Can consuming flavonoids restore old microglia to their youthful state?. Nutr Rev 2010, 68:719-728. 10.1111/j.1753-4887.2010.00336.x, 3058829, 21091915.
52. Rice-Evans C. Flavonoid antioxidants. Curr Med Chem 2001, 8:797-807.
53. Rice-Evans C. Flavonoids and isoflavones: absorption, metabolism, and bioactivity. Free Radic Biol Med 2004, 36:827-828. 10.1016/j.freeradbiomed.2003.12.012, 15019967.
54. Hollman PC, Katan MB. Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother 1997, 51:305-310. 10.1016/S0753-3322(97)88045-6, 9436520.
55. Day AJ, Mellon F, Barron D, Sarrazin G, Morgan MR, Williamson G. Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin. Free Radic Res 2001, 35:941-952. 10.1080/10715760100301441, 11811545.
56. Natsume M, Osakabe N, Oyama M, Sasaki M, Baba S, Nakamura Y, Osawa T, Terao J. Structures of (-)-epicatechin glucuronide identified from plasma and urine after oral ingestion of (-)-epicatechin: differences between human and rat. Free Radic Biol Med 2003, 34:840-849. 10.1016/S0891-5849(02)01434-X, 12654472.
57. Youdim KA, Qaiser MZ, Begley DJ, Rice-Evans CA, Abbott NJ. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med 2004, 36:592-604. 10.1016/j.freeradbiomed.2003.11.023, 14980703.
58. Peng HW, Cheng FC, Huang YT, Chen CF, Tsai T. Determination of naringenin and its glucuronide conjugate in rat plasma and brain tissue by high-performance liquid chromatography. J Chromatogr B: Biomed Sci Appl 1998, 714:369-374.
59. Peng HW, Huang YT, Chen CF, Tsai TH. Glucuronidation of naringenin in rats. Planta Med 1998, 64:779-790. 10.1055/s-2006-957587, 9933999.
60. Diamond BJ, Shiflett SC, Feiwel N, Matheis RJ, Noskin O, Richards JA, Schoenberger NE. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 2000, 81:668-678.
61. Jeremitsky E, Omert L, Dunham CM, Protetch J, Rodriguez A. Harbingers of poor outcome the day after severe brain injury: hypothermia, hypoxia, and hypoperfusion. J Trauma 2003, 54:312-319. 10.1097/01.TA.0000037876.37236.D6, 12579057.
62. Jones PA, Andrews PJ, Midgley S, Anderson SI, Piper IR, Tocher JL. Measuring the burden of secondary insults in head-injured patients during intensive care. J Neurosurg Anesthesiol 1994, 6:4-14.
63. McHugh GS, Engel DC, Butcher I, Steyerberg EW, Lu J, Mushkudiani N, Hernández AV, Marmarou A, Maas AI, Murray GD. Prognostic value of secondary insults in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007, 24:287-293. 10.1089/neu.2006.0031, 17375993.
64. Mushkudiani NA, Engel DC, Steyerberg EW, Butcher I, Lu J, Marmarou A, Slieker F, McHugh GS, Murray GD, Maas AI. Prognostic value of demographic characteristics in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007, 24:259-269. 10.1089/neu.2006.0028, 17375990.
65. Silverston P. Pulse oximetry at the roadside: a study of pulse oximetry in immediate care. BMJ 1989, 298:711-713. 10.1136/bmj.298.6675.711, 1836004, 2496817.
66. Chesnut RM. Guidelines for the management of severe head injury: what we know and what we think we know. J Trauma 1997, 42(5 Suppl):S19-S22.
67. Newcombe VF, Williams GB, Scoffings D, Cross J, Carpenter TA, Pickard JD, Menon DK. Aetiological differences in neuroanatomy of the vegetative state: insights from diffusion tensor imaging and functional implications. J Neurol Neurosurg Psychiatry 2010, 81:552-561. 10.1136/jnnp.2009.196246, 20460593.
68. Adams JH, Graham DI, Murray LS, Scott G. Diffuse axonal injury due to nonmissile head injury in humans: an analysis of 45 cases. Ann Neurol 1982, 12:557-563. 10.1002/ana.410120610, 7159059.
69. Eckmann F, Schlag H. Controlled double-blind study for the determination of the effect of Tebonin forte in patients with cerebrovascular insufficiency. Fortschr Med 1982, 100:1474-1478.
70. Halama P. Ginkgo biloba: effectiveness of a special extract in patients with cerebral insufficiency. Munch Med Wochenschr 1991, 133:190-194.
71. Halama P, Bartsch G, Meng G. Disorders of brain performance of vascular origin. Randomized double-blind study of the effectiveness of Gingko biloba extract. Fortschr Med 1988, 106:408-412.
72. Arrigo CS, Weitbrecht WV. Clinical and Psychometric Evaluation of Ginkgo Biloba Extract in Chronic Cerebrovascular Diseases 1985, John Libbey & Company, London.
73. Chao JC, Chu CC. Effects of Ginkgo biloba extract on cell proliferation and cytotoxicity in human hepatocellular carcinoma cells. World J Gastroenterol 2004, 10:37-41.
74. Le Bars KMM, Berman N, Le Bars KMM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997, 278:1327-1332. 10.1001/jama.1997.03550160047037, 9343463.
75. Moreau JP, Eck CR, McCabe J, Skinner S. Absorption, distribution and elimination of a labelled extract of Ginkgo biloba leaves in the rat. Presse Med 1986, 15:1458-1461.
76. Itil T, Martorano D. Natural substances in psychiatry (Ginkgo biloba in dementia). Psychopharmacol Bull 1995, 31:147-158.
77. Giunta B, Hou H, Zhu Y, Salemi J, Ruscin A, Shytle RD, Tan J. Fish oil enhances anti-amyloidogenic properties of green tea EGCG in Tg2576 mice. Neurosci Lett 2010, 471:134-138. 10.1016/j.neulet.2010.01.026, 20096749.
78. Lovell MK FM. Neuropsychiatry of Traumatic Brain Injury. Neuropsychological assessment 1994, 152-153. American Psychiatric Press, Washington, DC.
79. Di Giovanni S, Movsesyan V, Ahmed F, Cernak I, Schinelli S, Stoica B, Faden AI. Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci U S A 2005, 102:8333-8338. 10.1073/pnas.0500989102, 1149422, 15923260.
80. Chen SF, Hsu CW, Huang WH, Wang JY. Post-injury baicalein improves histological and functional outcomes and reduces inflammatory cytokines after experimental traumatic brain injury. Br J Pharmacol 2008, 155:1279-1296. 10.1038/bjp.2008.345, 2607198, 18776918.
81. Itoh T, Imano M, Nishida S, Tsubaki M, Hashimoto S, Ito A, Satou T. (-)-Epigallocatechin-3-gallate protects against neuronal cell death and improves cerebral function after traumatic brain injury in rats. Neuromol Med 2011, 13:300-309.
82. Fernandez JW, Rezai-Zadeh K, Obregon D, Tan J. EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP. FEBS Lett 2011, 584:4259-4267.
83. Corrigan F, Pham CL, Vink R, Blumbergs PC, Masters CL, van den Heuvel C, Cappai R. The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains. Brain Res 2011, 1378:137-143.
84. Thornton E, Vink R, Blumbergs PC, Van Den Heuvel C. Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. Brain Res 2006, 1094:38-46. 10.1016/j.brainres.2006.03.107, 16697978.
85. Giunta B, Obregon D, Hou H, Zeng J, Sun N, Nikolic V, Ehrhart J, Shytle D, Fernandez F, Tan J. EGCG mitigates neurotoxicity mediated by HIV-1 proteins gp120 and Tat in the presence of IFN-gamma: role of JAK/STAT1 signaling and implications for HIV-associated dementia. Brain Res 2006, 1123:216-225. 10.1016/j.brainres.2006.09.057, 17078933.
86. Giunta B, Zhou Y, Hou H, Rrapo E, Fernandez F, Tan J. HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide. Int J Clin Exp Pathol 2008, 1:260-275. 2480563, 18784813.
87. Rrapo E, Zhu Y, Tian J, Hou H, Smith A, Fernandez F, Tan J, Giunta B. Green tea-EGCG reduces GFAP associated neuronal loss in HIV-1 Tat transgenic mice. Am J Transl Res 2009, 1:72-79. 2776283, 19966940.
88. Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, Shytle RD, Tan J. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 2008, 1214:177-187.
89. Obregon DF, Rezai-Zadeh K, Bai Y, Sun N, Hou H, Ehrhart J, Zeng J, Mori T, Arendash GW, Shytle D, Town T, Tan J. ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 2006, 281:16419-16427. 10.1074/jbc.M600617200, 16624814.
90. Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 2005, 25:8807-8814. 10.1523/JNEUROSCI.1521-05.2005, 16177050.
91. Jang SW, Lee JW, Park SH, Kim JH, Yoo M, Na DH, Lee KC. Gastroretentive drug delivery system of DA-6034, a new flavonoid derivative, for the treatment of gastritis. Int J Pharm 2008, 356:88-94. 10.1016/j.ijpharm.2007.12.042, 18276090.
92. Chen X, Yin OQ, Zuo Z, Chow MS. Pharmacokinetics and modeling of quercetin and metabolites. Pharm Res 2005, 22:892-901. 10.1007/s11095-005-4584-1, 15948033.
93. Ley EJ, Clond MA, Singer MB, Shouhed D, Salim A. IL6 deficiency affects function after traumatic brain injury. J Surg Res 2011, 170:253-256. 10.1016/j.jss.2011.03.006, 21529825.
94. Dirscherl K, Karlstetter M, Ebert S, Kraus D, Hlawatsch J, Walczak Y, Moehle C, Fuchshofer R, Langmann T. Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. J Neuroinflamm 2010, 7:3-16.
95. Kavon R-Z, Jared E, Yun B, Sanberg PR, Paula B, Jun T, Douglas Shytle R. Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression. J Neuroinflamm 2008, 5:41.
96. Jang S, Dilger RN, Johnson RW. Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice. J Nutr 2010, 140:1892-1898. 10.3945/jn.110.123273, 2937579, 20685893.
97. Zheng LT, Ock J, Kwon BM, Suk K. Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. Int Immunopharmacol 2008, 8:484-494. 10.1016/j.intimp.2007.12.012, 18279803.
98. Lee H, Kim YO, Kim H, Kim SY, Noh HS, Kang SS, Cho GJ, Choi WS, Suk K. Flavonoid wogonin from medicinal herb is neuroprotective by inhibiting inflammatory activation of microglia. FASEB J 2003, 17:1943-1944.
99. Wang X, Chen S, Ma G, Ye M, Lu G. Genistein protects dopaminergic neurons by inhibiting microglial activation. Neuroreport 2005, 16:267-270. 10.1097/00001756-200502280-00013, 15706233.
100. Bureau G, Longpre F, Martinoli MG. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res 2008, 86:403-410. 10.1002/jnr.21503, 17929310.